Antiapoptotic role of growth factors in the myelodysplastic syndromes: Concordance between in vitro and in vivo observations

Clinical Cancer Research

Volumn 11, Issue 17, 2005, Pages 6291-6299

  Tehranchi, Ramin ^a,b   Fadeel, Bengt ^a   Schmidt Mende, Jan ^a   Forsblom, Ann Mari ^a   Emanuelsson, Emma ^a   Jadersten, Martin ^a   Christensson, Birger ^b   Hast, Robert ^b   Howe, Robert B ^d   Samuelsson, Jan ^c   Zhivotovsky, Boris ^a   Hellström Lindberg, Eva ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYTOCHROME C; ERYTHROPOIETIN; GLYCOPHORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GROWTH FACTOR; MITOCHONDRIAL ENZYME;

ANTIAPOPTOTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL GROWTH; CELL MATURATION; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LOCALIZATION; ENZYME RELEASE; ERYTHROBLAST; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; TRISOMY 8;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; APOPTOSIS; BONE MARROW CELLS; CASPASES; CYTOCHROMES C; ENZYME ACTIVATION; ERYTHROID PROGENITOR CELLS; ERYTHROPOIETIN, RECOMBINANT; GLYCOPHORIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; MONOSOMY; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; TRISOMY;

EID: 24344507215     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1850     Document Type: Article

References (31)

1. Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 1997;21:415-25.
2. Remacha AF, Arrizabalaga B, Villegas A, et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 1999;84: 1058-64.
3. Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000;109:367-75.
4. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 2004;103: 3265-70.
5. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87:4076-81.
6. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998;92: 68-75.
7. Tehranchi R, Fadeel B, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003;101:1080-6.
8. Morel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993;7:1315-23.
9. Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998;92:1910-7.
10. Pedersen-Bjergaard J, Christiansen DH, Andersen MK, Skovby F. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia 2002;16:2177-84.
11. Nilsson L, Astrand-Grundstrom I, Anderson K, et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1 (+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002;100:259-67.
12. Yan J, Whittom R, Delage R, Drouin R. A unique clone involving multiple structural chromosome rearrangements in a myelodysplastic syndrome case. Cancer Genet Cytogenet 2003;140:138-44.
13. Boultwood J, Lewis S, Wainscoat JS. The 5q- syndrome. Blood 1994;84:3253-60.
14. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World health organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
15. Rigolin GM, Porta MD, Bigoni R, et al. rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. Br J Haematol 2002;119:652-9.
16. Hellstrom-Lindberg E, Schmidt-Mende J, Forsblom AM, Christensson B, Fadeel B, Zhivotovsky B. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001;112:714-26.
17. Schmidt-Mende J, Tehranchi R, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 2001;15:742-51.
18. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78: 2791-808.
19. Miyamoto T, Iwasaki H, Reizis B, et al. Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev Cell 2002;3:137-47.
20. Richards MK, Liu F, Iwasaki H, Akashi K, Link DC. Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway. Blood 2003;102:3562-8.
21. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytoki.nes and bacterial products. Blood 1992;80:2012-20.
22. Brach MA, deVos S, Gruss HJ, Herrmann F. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood 1992;80:2920-4.
23. Dibbert B, Weber M, Nikolaizik WH, et al. Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: a general mechanism to accumulate effector cells in inflammation. Proc Natl Acad Sci USA 1999;96:13330-5.
24. Maianski NA, MuL FP, van Buul JD, Roos D, Kuijpers TW. Granulocyte colony-stimulating factor inhibits the mitochondria-dependent activation of caspase-3 in neutrophils. Blood 2002;99:672-9.
25. Carlsson G, Aprikyan AA, Tehranchi R, et al. Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells. Blood 2004; 103:3355-61.
26. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:378-81.
27. May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 α in association with suppression of apoptosis. J Biol Chem 1994;269: 26865-70.
28. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bel-XL and Bcl-2. Blood 1996;88:1576-82.
29. Gregory T, Yu C, Ma A, Orkin SH, Blobel GA. Weiss MJ. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood 1999;94:87-96.
30. Sloand EM, Kim S, Fuhrer M, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002; 100:4427-32.
31. Hast R, Wallvik J, Folin A, Bernell P, Stenke L. Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leuk Res 2001;25:13-8.